Effect of gender on clinical and epidemiologic features of Lyme borreliosis

Vector-Borne and Zoonotic Diseases

Volumn 7, Issue 1, 2007, Pages 34-41

  Bennet, Louise ^a,b   Stjernberg, Louise ^b,c   Berglund, Johan ^b,c  

^a LUND UNIVERSITY   (Sweden)

^b Blekinge Institute of Research and Development   (Sweden)

^c BLEKINGE INSTITUTE OF TECHNOLOGY   (Sweden)

Author keywords

Borrelia afzelii; Borrelia burgdorferi; Borrelia garinii; Erythema migrans; Lyme borreliosis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; INFANT; LYME DISEASE; MAJOR CLINICAL STUDY; MALE; NEWBORN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SEX DIFFERENCE; SWEDEN; TICK BITE;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANIMALS; ARACHNID VECTORS; BITES AND STINGS; BORRELIA BURGDORFERI GROUP; CHILD; CHILD, PRESCHOOL; ERYTHEMA CHRONICUM MIGRANS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; LYME DISEASE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS; SWEDEN; TICKS;

BORRELIA; BORRELIA AFZELII; BORRELIA BURGDORFERI; BORRELIA GARINII; IXODIDA;

EID: 34247278195     PISSN: 15303667     EISSN: None     Source Type: Journal    
DOI: 10.1089/vbz.2006.0533     Document Type: Article

References (39)

1. Åsbrink E, Olsson I. Clinical manifestations of erythema chronicum migrans afzelius in 161 patients. Acta Derm Venereol (Stockh) 1985; 65:43-52.
2. Asbrink E, Brehmer-Andersson E, Hovmark A. Acrodermatitis chronica atrophicans - a spirochitosis. Clinical and histopathological picture based on 32 patients; course and relationship to erythema chronicum migrans Afzelii. Am J Dermatopathol 1986; 8:209-219.
3. Åsbrink E, Olsson I, Hovmark A. Clinical manifestations of erythema chronicum migrans Afzelius in Sweden. A study of 231 patients. Z Bakt Hyg (A) 1986; 263:229-236.
4. Åsbrink E, Hovmark A. Lyme borreliosis: aspects of tickborne borrelia burgdorferi infection from a dermatologic viewpoint. Semin Dermatol 1990; 9:277-291.
5. Bennet L, Berglund J. Reinfection with Lyme Borreliosis: a retrospective follow-up study in southern Sweden. Scand J Infect Dis 2002; 34:183-186.
6. Bennet L, Fraenkel CJ, Garpmo U, Hailing A, et al. Clinical appearance of erythema migrans caused by B. afzelii and B. garinii - effect of the patient's sex. Wien Klin Wochenschr 2006a; 118:531-537.
7. Bennet L, Hailing A, Berglund J. Warm humid summers and mild winters increase the incidence rate of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 2006b; 25:426-432.
8. Berglund J, Eitrem R, Ornstein K, Lindberg A, et al. An epidemiologic study of Lyme disease in southern Sweden. N Engl J Med 1995; 333:1319-1324.
9. Berglund J, Stjernberg L, Ornstein K, Tykesson-Joelsson K, et al. 5-y follow-up study of patients with neuroborreliosis. Scan J Infect Dis 2002; 34:421-425.
10. Berger B. Erythema chronicum migrans of Lyme disease. Arch Dermatol 1984; 120:1017-1021.
11. Carlsson SA, Granlund H, Jansson C, Nyman D, et al. Characteristics of erythema migrans in Borrelia afzelii and Borrelia garinii infections. Scand J Infect Dis 2003; 35:31-33.
12. Connecticut Department of Public Health. Lyme disease - Connecticut, 2000. Connecticut Epidemiologist 2001; 21:9-12.
13. Eisen L, Lane RS. Vectors of Borrelia burgdorferi sensu lato. In: Gray JS, Kahl O, Lane RS, Stanek G, eds. Lyme boreliosis; Biology, Epidemiology and Control. Trowbridge, UK: Cromwell Press, CABI Publishing; 2002:91-115.
14. European Union Concerted Action on Lyme Borreliosis. 1997-2005. Clinical features of Erythema migrans. Available from: www.oeghmp.at/eucalb/ diagnosis_clinical-features-ds.html.
15. Hollström E. Penicillin treatment of erythema chronicum migrans Afzelius. Acta Derm Venereol (Stockh) 1958; 38:285-289.
16. Jarefors S, Bennet L, You E, Forsberg P, et al. Lyme borreliosis reinfection: might it be explained by a gender difference in immune response? Immunology 2006; 118:224-232.
17. Logar M, Ruzić-Sabljić E, Maraspin V, Lotric-Furlan S, et al. Comparison of erythema migrans caused by Borrelia afzelii and Borrelia garinii. Infection 2004; 32:15-19.
18. nd ed. Heidelberg, Germany: Springer Verlag; Available at: www.parasitology.informatik.uniwuerzburg.de/login/n/h/1453.html
19. Mehnert WH, Krause G. Surveillance of Lyme borreliosis in Germany 2002 and 2003. Eur Surveill 2005; 10:83-85.
20. Müllegger RR. Clinical aspects and diagnosis of erythema migrans and borrelia lymphocytoma. Acta Dermatovenerologica APA 2001; 10(4) Available at: www.mf.uni-lj.si/acta-apa/acta-apa-01-4.html
21. Olsén NJ, Kovacs WJ. Gonadal steroids and immunity. Endocr Rev 1996; 17:369-384.
22. Orloski KA, Hayes EB, Campbell GL, Dennis DT. Surveillance for Lyme disease - United States, 1992-1998. MMWR CDC Surveill Summ 2000; 28;49:1-11.
23. Pirilä V. The penicillin treatment of acrodermatitis chronica atrophicans. Acta Derm Venereol (Stockh) 1951; 31:576-591.
24. Randolph SE. The shifting landscape of tick-borne zoonoses: tick-borne encephalitis and Lyme borreliosis in Europe. Phil. Trans. R. Soc. Lond. B. 2001; 356:1045-1056.
25. Smith RP, Schoen RT, Rahn DW, Sikand VK et al. Clinical characteristics and treatment outcome of early Lyme disease in patients with microbiologically confirmed Erythema Migrans. Ann Intern Med 2002; 136:421-428.
26. Smittskyddsinstitutet. 2005. Available at: www.smittsky-ddsinstitutet.se/ SMItemplates/BigArticle6088.aspx
27. Stanek G, Flamm H, Groh V, Hirschl A, et al. Epidemiology of borrelia infections in Austria. Zentralbl Bakteriol Mikrobiol Hyg [A] 1987; 263:442-449.
28. Stanek G, Strle F. Lyme borreliosis. Lancet. 2003; 362:1639-1647.
29. Statistics Sweden. 1982-1999. Available at: www.scb.se/templates/ Listning20938.asp
30. Steere AC, Bartenhagen NH, Craft JE, Hutchinson GJ et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983; 99:76-82.
31. Sternberg L, Berglund L. Tick prevention among a population living in a highly endemic area. Scand J Public Health 2005; 33:432-438.
32. Sternberg L, Berglund J. Risk of acquiring tick bites in south-eastern Sweden. Scand J Infect Dis 2002; 4:840-844.
33. Strle F, Nadelman RB, Cimperman J, Nowakowski J, et al. Comparison of culture-confirmed erythema migrans caused by Borrelia burgdorferi sensu stricto in New York and by Borrelia afzelii in Slovenia. Ann Intern Med 1999; 130:32-36.
34. Strle F. Lyme borreliosis in Slovenia. Zentralbl Bakteriol 1999; 289:643-652.
35. Strle F, Videcnik J, Zorman P, Cimperman J, et al. Clinical and epidemiological findings for atients with erythema migrans. Comparison of cohorts from the years 1993 and 2000. Wien Klin Wochenschr 2002; 31;114:493-497.
36. Thyresson N. The penicillin treatment of acrodermatitis chronica atrophicans. Acta Derm Venereol (Stock) 1949; 29:572-621.
37. Wahlberg P, Garnlund H, Nyman D, Panelius J, et al. Late Lyme borreliosis: epidemiology, diagnosis and clinical features. Ann Med 1993; 25:349-352.
38. Weber K, Puznik A, Becker T. Erythema migrans-Krankheit.Beitrag zur Klinik und Bezeihung zur Lyme-Krankheit. Dtch Med Wschr 1983; 109:1182-1190.
39. Widhe M. Immune responses in human Lyme borreliosis. Cytokines and IgG subclasses in relation to clinical outcome. Linköping, Sweden: Linköping University Medical Dissertations No. 778, 2003.